Trytosaveabitスレ主jimmy the trader:
GL! I’m still looking for a buy signal? I do think there is a chance this may start to move on a delayed reaction from todays PR? Wouldn’t be the first time! Hehehe
$フルクラム セラピューティクス(FULC.US)$Reuters· 2 mins ago Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
$フルクラム セラピューティクス(FULC.US)$ NEWS Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024. P...
Fulcrum Therapeutics' falling operating revenue and significant cash burn relative to market value pose risks, despite a 13% cut in cash burn last year. The promising cash runway should be assessed against possible future fundraising costs.
$フルクラム セラピューティクス(FULC.US)$Therapeutics Now Expects That Its Existing Cash And Equivalents To Be Sufficient To Fund Its Operating Requirements Into 2026, An Update To Prior Guidance Of Mid-2025
Haymaker78 :
I appreciate you posting this, I am new to your content- apologies if this is a stupid question. What are your watchlists for? Are these stocks you are bullish on for the next trading day?
フルクラム セラピューティクスに関するコメント
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
NEWS
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
P...
まだコメントはありません